In CY 2015, incident data was analyzed with respect to seven regions of the world. PSI recorded a total of 3,002 pharmaceutical crime incidents. Every region experienced a pharmaceutical crime incident. In total, there were 128 countries found to have been impacted by pharmaceutical crime.
PSI documented a thirty-eight percent increase (+38%) in the worldwide incident total compared to the previous year. Incidents impacting the Asia Pacific region surpassed one thousand incidents annually for the first time in CY 2015. Also, incidents in North America increased over one hundred percent from the previous year.
In the adjacent chart, the regions are ranked in order from those experiencing the highest number of incidents to those with the lowest number of incidents.
It is important to note that the regions that are more frequently linked to incidents are not necessarily those with weak enforcement and inspection programs. Rather, countries in these regions are effectively identifying pharmaceutical crime through law enforcement activity and inspections by drug regulatory agencies. Many countries in regions with high incident totals are quite transparent in government operations and their activities are known to the media and public.
Those regions with seemingly low incident totals are not necessarily unaffected by or at a lower risk of pharmaceutical crime. Due to competing law enforcement priorities, lack of funding or inadequate regulatory structures, in certain regions of the world, counterfeit medicines often go undetected. It is important to recognize these facts, since they complicate region to region comparisons.